Cargando…
Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promising antitumor activity in preclinical studies. However, the efficacy of recombinant TRAIL in clinical trials is compromised by its short serum half-life and low in vivo stability. Induction of endogenous TRAIL may overcome t...
Autores principales: | Liu, Shuang, Polsdofer, Erik V., Zhou, Lukun, Ruan, Sanbao, Lyu, Hui, Hou, Defu, Liu, Hao, Thor, Ann D., He, Zhimin, Liu, Bolin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167201/ https://www.ncbi.nlm.nih.gov/pubmed/34141868 http://dx.doi.org/10.1016/j.omto.2021.04.012 |
Ejemplares similares
-
Synergistic antitumor effects of circularly permuted TRAIL with doxorubicin in triple-negative breast cancer: Circularly permuted TRAIL with Dox in TNBC
por: Liu, Jia, et al.
Publicado: (2023) -
HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
por: Lyu, Hui, et al.
Publicado: (2023) -
HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells
por: Lyu, Hui, et al.
Publicado: (2023) -
Understanding the biology of HER3 receptor as a therapeutic target in human cancer
por: Lyu, Hui, et al.
Publicado: (2018) -
Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo
por: Liu, Hao, et al.
Publicado: (2023)